Correction: Should Remdesivir Be Used for the Treatment of Patients With COVID-19?
Authors: Amir Qaseem, MD, PhD, MHA, Jennifer Yost, PhD, RN, Itziar Etxeandia-Ikobaltzeta, PharmD, PhD, George M. Abraham, MD, MPH, Janet A. Jokela, MD, MPH
Journal: Annals of Internal Medicine (2021)

CorrectionsJuly 2021Correction: Should Remdesivir Be Used for the Treatment of Patients With COVID-19?FREEThis correction concerns the following article:Clinical GuidelinesMay 2021Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)FREEAmir Qaseem, MD, PhD, MHA, Jennifer Yost, PhD, RN, Itziar Etxeandia-Ikobaltzeta, PharmD, PhD, George M. Abraham, MD, MPH, Janet A. Jokela, MD, MPHAmir Qaseem, MD, PhD, MHAAmerican College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E.), Jennifer Yost, PhD, RNAmerican College of Physicians, Philadelphia, and Villanova University, Villanova, Pennsylvania (J.Y.), Itziar Etxeandia-Ikobaltzeta, PharmD, PhDAmerican College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E.), George M. Abraham, MD, MPHUniversity of Massachusetts Medical School and Saint Vincent Hospital, Worcester, Massachusetts (G.M.A.), Janet A. Jokela, MD, MPHUniversity of Illinois College of Medicine at Urbana-Champaign, Champaign, Illinois (J.A.J.)https://doi.org/10.7326/L21-0258 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In the American College of Physicians' rapid, living practice points (1), the first footnote of Table 1 contained an error. The alanine aminotransferase threshold at which remdesivir therapy should be discontinued is more than 10 times the upper limit of normal rather than 5 or more times the upper limit of normal. Because this was reported correctly in Table 3, it was deleted from the footnote of Table 1. In addition, an incorrect citation to reference 5 for this statement was removed from Table 3. These corrections do not affect the overall conclusions of the article.The online version has been corrected.Reference1. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19? Rapid, living practice points from the American College of Physicians (version 2). Ann Intern Med. 2021;174:673-9. [PMID: 33560862]. doi:10.7326/M20-8101 LinkGoogle Scholar Comments0 CommentsSign In to Submit A Comment PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoShould Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2) Amir Qaseem , Jennifer Yost , Itziar Etxeandia-Ikobaltzeta , George M. Abraham , Janet A. Jokela , Mary Ann Forciea , Matthew C. Miller , and Linda L. Humphrey , for the Scientific Medical Policy Committee of the American College of Physicians* Metrics July 2021Volume 174, Issue 7Page: 1040KeywordsCOVID-19DisclosureDrugsExtracorporeal membrane oxygenationMortalityNetwork analysisOxygenPatientsSystematic reviewsVentilators ePublished: 20 July 2021 Issue Published: July 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...